➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
AstraZeneca
Moodys
Mallinckrodt
Dow

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CERC-501

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for CERC-501?

CERC-501 is an investigational drug.

There have been 7 clinical trials for CERC-501. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Duke University.

There are five US patents protecting this investigational drug and seventy international patents.

Recent Clinical Trials for CERC-501
TitleSponsorPhase
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung InjuryAevi Genomic Medicine, LLC, a Cerecor companyPhase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?Cerecor IncPhase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?National Institute on Drug Abuse (NIDA)Phase 2

See all CERC-501 clinical trials

Clinical Trial Summary for CERC-501

Top disease conditions for CERC-501
Top clinical trial sponsors for CERC-501

See all CERC-501 clinical trials

US Patents for CERC-501

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CERC-501   Start Trial Heteroarylphenoxy benzamide kappa opioid ligands Pfizer Inc. (New York, NY)   Start Trial
CERC-501   Start Trial Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features H. LUNDBECK A/S (Valby, DK)   Start Trial
CERC-501   Start Trial Kappa selective opioid receptor antagonist Eli Lilly and Company (Indianapolis, IN)   Start Trial
CERC-501   Start Trial Kappa selective opioid receptor antagonist Eli Lilly and Company (Indianapolis, IN)   Start Trial
CERC-501   Start Trial 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists RESEARCH TRIANGLE INSTITUTE (Research Triangle Park, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CERC-501

Drugname Country Document Number Estimated Expiration Related US Patent
CERC-501 Australia 2017365123 2036-11-28   Start Trial
CERC-501 Canada 3045242 2036-11-28   Start Trial
CERC-501 China 110234638 2036-11-28   Start Trial
CERC-501 European Patent Office 3544972 2036-11-28   Start Trial
CERC-501 Israel 266962 2036-11-28   Start Trial
CERC-501 Japan 2019535799 2036-11-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
AstraZeneca
Moodys
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.